MX2024005415A - Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. - Google Patents

Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados.

Info

Publication number
MX2024005415A
MX2024005415A MX2024005415A MX2024005415A MX2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
antibodies
humanized anti
cell
prophylactic
Prior art date
Application number
MX2024005415A
Other languages
English (en)
Spanish (es)
Inventor
James Kranz
Original Assignee
Kiniksa Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals Gmbh filed Critical Kiniksa Pharmaceuticals Gmbh
Publication of MX2024005415A publication Critical patent/MX2024005415A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024005415A 2021-11-05 2022-11-01 Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. MX2024005415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163276363P 2021-11-05 2021-11-05
PCT/US2022/079072 WO2023081652A1 (en) 2021-11-05 2022-11-01 Pharmaceutical compositions of humanized anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
MX2024005415A true MX2024005415A (es) 2024-07-30

Family

ID=86242030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005415A MX2024005415A (es) 2021-11-05 2022-11-01 Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados.

Country Status (9)

Country Link
US (2) US20230279135A1 (https=)
EP (1) EP4426744A4 (https=)
JP (1) JP2024540377A (https=)
KR (1) KR20240095255A (https=)
CN (1) CN118382640A (https=)
AU (1) AU2022381078A1 (https=)
CA (1) CA3236827A1 (https=)
MX (1) MX2024005415A (https=)
WO (1) WO2023081652A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
BR112018004296B1 (pt) * 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos

Also Published As

Publication number Publication date
KR20240095255A (ko) 2024-06-25
JP2024540377A (ja) 2024-10-31
EP4426744A4 (en) 2025-10-22
WO2023081652A1 (en) 2023-05-11
US20230279135A1 (en) 2023-09-07
EP4426744A1 (en) 2024-09-11
AU2022381078A1 (en) 2024-05-23
US20250282884A1 (en) 2025-09-11
CN118382640A (zh) 2024-07-23
CA3236827A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
MX2024005415A (es) Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados.
CR20180484A (es) Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos
AR127010A2 (es) Anticuerpo, moléculas relacionadas, célula huesped, método de preparación y composición farmacéutica
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
MX2024001205A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso.
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
RU2018134595A (ru) Композиции, включающие антитела к cd38 и карфилзомиб
MX2018002708A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
ME02533B (me) BISPECIFIČNA ANTITELA PROTIV CD3-EPSILON l BCMA
PE20211396A1 (es) Receptores quimericos de dll3 y metodos para su uso
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
CO6640239A2 (es) Proceso par preparar una composición de inmunoglobulina
RU2016115866A (ru) Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
BR112017016434A8 (pt) Cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1 e para cristalizar um anticorpo monoclonal anti-pd-1, bem como e composição farmacêutica e seu uso
AR086823A1 (es) Formulaciones de anticuerpo anti-c-met, metodos
RU2015110981A (ru) Комбинации и их применение
PE20091655A1 (es) Farmaco para el cancer de higado
MX380191B (es) Combinaciones de modalidades para el tratamiento de la diabetes.
AR125473A1 (es) Conjugados de anticuerpo anti-c-met y fármaco
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
CL2024002016A1 (es) Anticuerpo modificado anti-pd-l1 humano; composición farmacéutica; y uso para tratar una enfermedad neurodegenerativa.
SA522432999B1 (ar) C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها
NI201700077A (es) Ácidos piridil-cicloalquil-carboxílico sustituidos, composiciones que los contienen y usos de los mismos.
IN2014DN03077A (https=)
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso